NASDAQ:DVAX - Dynavax Technologies Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $6.35 -0.01 (-0.16 %) (As of 05/23/2019 04:00 PM ET)Previous Close$6.36Today's Range$6.30 - $6.3952-Week Range$5.89 - $17.05Volume814,525 shsAverage Volume1.06 million shsMarket Capitalization$413.16 millionP/E RatioN/ADividend YieldN/ABeta0.6 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Its product candidates include SD-101, a cancer immunotherapy that is in Phase 2 clinical trials; DV281, an investigational TLR9 agonist, which is in Phase I clinical trial for the treatment of non-small cell lung cancer; and AZD1419, which is in Phase IIa clinical trial to treat asthma. Dynavax Technologies Corporation has a collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California. Receive DVAX News and Ratings via Email Sign-up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:DVAX Previous Symbol CUSIP26815810 CIK1029142 Webhttp://www.dynavax.com/ Phone510-848-5100Debt Debt-to-Equity Ratio4.88 Current Ratio5.27 Quick Ratio4.61Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$8.20 million Price / Sales50.38 Cash FlowN/A Price / Cash FlowN/A Book Value$0.66 per share Price / Book9.62Profitability EPS (Most Recent Fiscal Year)($2.55) Net Income$-158,900,000.00 Net Margins-1,156.11% Return on Equity-190.84% Return on Assets-63.36%Miscellaneous Employees249 Outstanding Shares65,064,000Market Cap$413.16 million Next Earnings Date8/5/2019 (Estimated) OptionableOptionable Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions What is Dynavax Technologies' stock symbol? Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX." How were Dynavax Technologies' earnings last quarter? Dynavax Technologies Co. (NASDAQ:DVAX) posted its quarterly earnings data on Wednesday, May, 8th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.67) by $0.05. The biopharmaceutical company earned $5.77 million during the quarter, compared to analyst estimates of $5.95 million. Dynavax Technologies had a negative net margin of 1,156.11% and a negative return on equity of 190.84%. The business's revenue for the quarter was up 3294.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.63) earnings per share. View Dynavax Technologies' Earnings History. When is Dynavax Technologies' next earnings date? Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Monday, August 5th 2019. View Earnings Estimates for Dynavax Technologies. What price target have analysts set for DVAX? 4 brokerages have issued twelve-month price objectives for Dynavax Technologies' shares. Their predictions range from $25.00 to $30.00. On average, they expect Dynavax Technologies' stock price to reach $27.6667 in the next year. This suggests a possible upside of 335.7% from the stock's current price. View Analyst Price Targets for Dynavax Technologies. What is the consensus analysts' recommendation for Dynavax Technologies? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies. Has Dynavax Technologies been receiving favorable news coverage? Press coverage about DVAX stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Dynavax Technologies earned a media sentiment score of 1.9 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. Who are some of Dynavax Technologies' key competitors? Some companies that are related to Dynavax Technologies include Zogenix (ZGNX), Zai Lab (ZLAB), Prestige Consumer Healthcare (PBH), Nabriva Therapeutics (NBRV), Madrigal Pharmaceuticals (MDGL), Innoviva (INVA), Endo International (ENDP), Heron Therapeutics (HRTX), Cambrex (CBM), Esperion Therapeutics (ESPR), Gossamer Bio (GOSS), Opko Health (OPK), Aimmune Therapeutics (AIMT), Apellis Pharmaceuticals (APLS) and Phibro Animal Health (PAHC). What other stocks do shareholders of Dynavax Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Array Biopharma (ARRY), Kite Pharma (KITE), United Continental (UAL), Cara Therapeutics (CARA) and Micron Technology (MU). Who are Dynavax Technologies' key executives? Dynavax Technologies' management team includes the folowing people: Mr. Eddie Gray, CEO & Director (Age 60)Dr. Dennis A. Carson Ph.D., M.D., Co-Founder, Director & Member of Scientific Advisory Board (Age 72)Mr. Michael S. Ostrach, CFO, Chief Bus. Officer & Sr. VP (Age 67)Mr. David F. Novack, Sr. VP of Operations & Quality (Age 57)Dr. Robert L. Coffman, Chief Scientific Officer & Sr. VP (Age 72) Who are Dynavax Technologies' major shareholders? Dynavax Technologies' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.51%), Federated Investors Inc. PA (5.86%), Chicago Capital LLC (3.98%), Eagle Asset Management Inc. (3.74%), Bain Capital Public Equity Management LLC (1.94%) and FMR LLC (1.67%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Institutional Ownership Trends for Dynavax Technologies. Which institutional investors are selling Dynavax Technologies stock? DVAX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, DekaBank Deutsche Girozentrale, Northern Trust Corp, Gables Capital Management Inc., Patriot Financial Group Insurance Agency LLC, Jane Street Group LLC and California State Teachers Retirement System. Company insiders that have sold Dynavax Technologies company stock in the last year include David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Insider Buying and Selling for Dynavax Technologies. Which institutional investors are buying Dynavax Technologies stock? DVAX stock was purchased by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Bain Capital Public Equity Management LLC, Rhenman & Partners Asset Management AB, Macquarie Group Ltd., Marshall Wace North America L.P., Federated Investors Inc. PA, BlackRock Inc. and Assenagon Asset Management S.A.. View Insider Buying and Selling for Dynavax Technologies. How do I buy shares of Dynavax Technologies? Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Dynavax Technologies' stock price today? One share of DVAX stock can currently be purchased for approximately $6.35. How big of a company is Dynavax Technologies? Dynavax Technologies has a market capitalization of $413.16 million and generates $8.20 million in revenue each year. The biopharmaceutical company earns $-158,900,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Dynavax Technologies employs 249 workers across the globe. What is Dynavax Technologies' official website? The official website for Dynavax Technologies is http://www.dynavax.com/. How can I contact Dynavax Technologies? Dynavax Technologies' mailing address is 2929 SEVENTH STREET SUITE 100, BERKELEY CA, 94710. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected] MarketBeat Community Rating for Dynavax Technologies (NASDAQ DVAX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 347 (Vote Outperform)Underperform Votes: 351 (Vote Underperform)Total Votes: 698MarketBeat's community ratings are surveys of what our community members think about Dynavax Technologies and other stocks. Vote "Outperform" if you believe DVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVAX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/23/2019 by MarketBeat.com StaffFeatured Article: What type of investment options does a Roth IRA provide? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.